Bettoli V, Naldi L, Cazzaniga S, Zauli S, Atzori L, Borghi A, et al. Overweight, diabetes and disease duration influence clinical severity in hidradenitis suppurativa-acne inversa: evidence from the national Italian registry. Br J Dermatol 2016;174(1):195-7. https://www.ncbi.nlm.nih.gov/pubmed/25913460
Deckers IE, Benhadou F, Koldijk MJ, Del Marmol V, Horvath B, Boer J, et al. Inflammatory bowel disease is associated with hidradenitis suppurativa: Results from a multicenter cross-sectional study. J Am Acad Dermatol 2017;76(1):49-53. https://www.ncbi.nlm.nih.gov/pubmed/27793450
Denny G, Anadkat MJ. The effect of smoking and age on the response to first-line therapy of hidradenitis suppurativa: An institutional retrospective cohort study. J Am Acad Dermatol 2017;76(1):54-9. https://www.ncbi.nlm.nih.gov/pubmed/27692736
Gold DA, Reeder VJ, Mahan MG, Hamzavi IH. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol 2014;70(4):699-703. https://www.ncbi.nlm.nih.gov/pubmed/24433875
Ingram JR, Collier F, Brown D, Burton T, Burton J, Chin MF, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol 2019;180(5):1009-17. https://www.ncbi.nlm.nih.gov/pubmed/30552762
Jennings L, Hambly R, Hughes R, Moriarty B, Kirby B. Metformin use in hidradenitis suppurativa. J Dermatolog Treat 2020;31(3):261-3. https://www.ncbi.nlm.nih.gov/pubmed/30893570
Miller IM, Ellervik C, Vinding GR, Zarchi K, Ibler KS, Knudsen KM, et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 2014;150(12):1273-80. https://www.ncbi.nlm.nih.gov/pubmed/25229996
